[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CN110168098A - 一种检测糖代谢异常的方法及其预防及治疗 - Google Patents

一种检测糖代谢异常的方法及其预防及治疗 Download PDF

Info

Publication number
CN110168098A
CN110168098A CN201680090803.8A CN201680090803A CN110168098A CN 110168098 A CN110168098 A CN 110168098A CN 201680090803 A CN201680090803 A CN 201680090803A CN 110168098 A CN110168098 A CN 110168098A
Authority
CN
China
Prior art keywords
gpx2
individual
expression
expression quantity
mouse
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680090803.8A
Other languages
English (en)
Inventor
余明隆
庄万龙
黄志富
戴嘉言
柯佑民
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kaohsiung Medical University
Original Assignee
Kaohsiung Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaohsiung Medical University filed Critical Kaohsiung Medical University
Publication of CN110168098A publication Critical patent/CN110168098A/zh
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44Oxidoreductases (1)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/28Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving peroxidase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y111/00Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01Peroxidases (1.11.1)
    • C12Y111/01009Glutathione peroxidase (1.11.1.9)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08RNA viruses
    • G01N2333/18Togaviridae; Flaviviridae
    • G01N2333/183Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/186Hepatitis C; Hepatitis NANB
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/902Oxidoreductases (1.)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/902Oxidoreductases (1.)
    • G01N2333/908Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/04Endocrine or metabolic disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/04Endocrine or metabolic disorders
    • G01N2800/042Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/50Determining the risk of developing a disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/70Mechanisms involved in disease identification
    • G01N2800/7057(Intracellular) signaling and trafficking pathways
    • G01N2800/7066Metabolic pathways
    • G01N2800/7071Carbohydrate metabolism, e.g. glycolysis, gluconeogenesis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)

Abstract

本发明是有关于一种检测糖类代谢异常的方法,包括检测检体中GPx2基因表达、GPx2蛋白表达量、或GPx2的蛋白活性,并与一正常个体的GPx2表达量进行比较,其中该个体的GPx2表达量显著低于该正常个体的GPx2表达量代表该个体具有糖类代谢异常的状态。本发明另提供一种GPx2用于制备治疗预防第二型糖尿病的医药组合物的用途。

Description

PCT国内申请,说明书已公开。

Claims (8)

  1. PCT国内申请,权利要求书已公开。
CN201680090803.8A 2016-11-14 2016-11-14 一种检测糖代谢异常的方法及其预防及治疗 Pending CN110168098A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2016/105759 WO2018086126A1 (zh) 2016-11-14 2016-11-14 一种检测糖代谢异常的方法及其预防及治疗

Publications (1)

Publication Number Publication Date
CN110168098A true CN110168098A (zh) 2019-08-23

Family

ID=62110166

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680090803.8A Pending CN110168098A (zh) 2016-11-14 2016-11-14 一种检测糖代谢异常的方法及其预防及治疗

Country Status (6)

Country Link
US (1) US11439689B2 (zh)
EP (1) EP3540072A4 (zh)
JP (1) JP7066209B2 (zh)
KR (1) KR20190077037A (zh)
CN (1) CN110168098A (zh)
WO (1) WO2018086126A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103470194B (zh) * 2013-09-07 2015-12-23 中国石油集团西部钻探工程有限公司 易上卸套管母扣护丝装置

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005046718A1 (en) * 2003-11-06 2005-05-26 Ohio University Diagnosis and hyperinsulinemia and type ii diabetes and protection against same based on genes differentially expressed in pancreas cells (12.1)
WO2005058142A2 (en) * 2003-12-16 2005-06-30 Emory University Diabetes diagnostic
WO2006056080A1 (en) * 2004-11-29 2006-06-01 Diagnocure Inc. Gpx2 a specific and sensitive target for lung cancer diagnosis, prognosis and/or theranosis
WO2010005533A2 (en) * 2008-06-30 2010-01-14 The Johns Hopkins University Compositions and methods for the treatment of ocular oxidative stress and retinitis pigmentosa
CN104651329A (zh) * 2014-02-18 2015-05-27 吉林大学 一种含有丝氨酸的谷胱甘肽过氧化物酶gpx2突变体及其制备方法
WO2016057574A1 (en) * 2014-10-06 2016-04-14 Memorial Sloan-Kettering Cancer Center Method to reduce oncogenic potential of induced pluripotent stem cells from aged donors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1256312A (zh) * 1998-10-29 2000-06-14 复旦大学 新的人谷胱苷肽过氧化酶、其编码序列及制法和用途
NZ580169A (en) 2003-10-23 2011-04-29 Illumigen Biosciences Inc Detection of mutations in a gene associated with resistance to viral infection, OAS1 (SEQ ID NO:48)
NZ606888A (en) 2009-04-16 2014-07-25 Taisho Pharmaceutical Co Ltd Pharmaceutical compositions for the treatment of diabetes mellitus

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005046718A1 (en) * 2003-11-06 2005-05-26 Ohio University Diagnosis and hyperinsulinemia and type ii diabetes and protection against same based on genes differentially expressed in pancreas cells (12.1)
WO2005058142A2 (en) * 2003-12-16 2005-06-30 Emory University Diabetes diagnostic
WO2006056080A1 (en) * 2004-11-29 2006-06-01 Diagnocure Inc. Gpx2 a specific and sensitive target for lung cancer diagnosis, prognosis and/or theranosis
WO2010005533A2 (en) * 2008-06-30 2010-01-14 The Johns Hopkins University Compositions and methods for the treatment of ocular oxidative stress and retinitis pigmentosa
CN104651329A (zh) * 2014-02-18 2015-05-27 吉林大学 一种含有丝氨酸的谷胱甘肽过氧化物酶gpx2突变体及其制备方法
WO2016057574A1 (en) * 2014-10-06 2016-04-14 Memorial Sloan-Kettering Cancer Center Method to reduce oncogenic potential of induced pluripotent stem cells from aged donors

Also Published As

Publication number Publication date
WO2018086126A1 (zh) 2018-05-17
EP3540072A1 (en) 2019-09-18
US20200093897A1 (en) 2020-03-26
US11439689B2 (en) 2022-09-13
JP2020513232A (ja) 2020-05-14
EP3540072A4 (en) 2020-05-20
KR20190077037A (ko) 2019-07-02
JP7066209B2 (ja) 2022-05-13

Similar Documents

Publication Publication Date Title
JP5602123B2 (ja) 標的細胞中のウイルスゲノム量を減少させるための方法および組成物
Copenhaver et al. Type 1 diabetes: where are we in 2017?
JP2012522013A (ja) 調節ires媒介翻訳
CN109593814A (zh) 筛选分析、鉴别药剂的方法及药物组合物
CN112274523A (zh) 一种治疗脂肪肝的药物和治疗方法
EP2351585A1 (en) Anti-hepatitis c virus composition
Zafar et al. Insulin detemir causes lesser weight gain in comparison to insulin glargine: role on hypothalamic NPY and galanin
CN110168098A (zh) 一种检测糖代谢异常的方法及其预防及治疗
KR101384360B1 (ko) Scf 또는 이의 수용체를 억제하는 물질을 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물
US20210403908A1 (en) Compositions and methods for treatment of hepatitis d virus infection
US10342852B2 (en) Methods of reducing blood glucose or triglyceride levels by administration of METRNL protein
TWI620933B (zh) 一種檢測醣類代謝異常的方法及其預防及治療
EP1631291B1 (en) Use of tyrosine kinase inhibitors to treat diabetes
JP7032775B2 (ja) 人工合成mRNAの発現を効率化する方法
US20200046700A1 (en) Focal adhesion kinase inhibitor as a therapeutic agent in diabetes
CN107184956B (zh) Metrnl蛋白或基因在防治脓毒血症方面的应用
AU2021226119B2 (en) Method for screening anticancer agent and combination drug of kinase inhibitors for treatment of pancreatic cancer
CN100372537C (zh) 酪氨酸激酶抑制剂在治疗糖尿病中的用途
Villarroya et al. Mechanisms of antiretroviral-induced mitochondrial dysfunction in adipocytes and adipose tissue: in-vitro, animal and human adipose tissue studies
Gravani et al. Post COVID-19 Infection Diffuse Patch Granuloma Annulare in a Female Patient with Rheumatoid Arthritis: A Case Report
US20110212160A1 (en) Configurable microscopic medical payload delivery device to deliver nuclear signaling proteins to specific cells to manage diabetes mellitus and genetic deficiency disorders
AU2022376087A1 (en) Method or agent with hdac regulator, for treatment of diabetes and complications
CN105348380A (zh) 犬成纤维细胞生长因子21及其在治疗犬内分泌疾病中的用途
WO2023281434A1 (en) Use of oligonucleotides for individuals with renal impairment
CN115813942A (zh) 梓醇在治疗糖尿病肝损伤的药物中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination